This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About

Burden of Disease

Burden of Disease

Description of the DiseaseGlobal EpidemiologyIndian EpidemiologyPneumococcal Disease and InfluenzaChallenges

Risk Factors
 

Risk Factors

Secondary Infections
​​​​​​​

Secondary Infections

Mechanism of Action
​​​​​​​

Mechanism of Action

Prevention of Pneumococcal Disease
 

Polysaccharide VaccineConjugate VaccineDifference

Need for Pneumococcal Vaccination

In ElderlyIn India

Cost-effectiveness of PCV13
 

NeedIndian StudiesGlobal Studies

Legacy of Prevenar
 

ManufacturingCRM197Activation and ConjugationPneumococcal Disease and InfluenzaDistributionVideos

Safety
 

Safety

Conclusion
 

Conclusion
Dosing

Dosing
 

Adults ≥18 Years of AgeAdults ≥50 Years of AgeCOVID VaccinationFlu Vaccination
Efficacy

Prevenar 13® Clinical Experience
 

IntroductionClinical Trials

Efficacy of Prevenar 13®
 

IntroductionStudyObjectiveMethodologyCriteriaResultsConclusion

Effectiveness of Prevenar 13® 
 

IntroductionObjectiveMethodologyAnalysisResultsLimitationsLearningsConclusion

Indian Clinical Trials
 

IntroductionStudy DesignResultsLimitationsConclusion
Recommendations for Use

Recommendations for Use
 

ACIP 2019NCCN 2020RSSDI 2020IMA GuidelinesIAOH Guidelines for Working AdultsClinical Practice Guidelines 2019 (ICS/NCCP)The Geriatric Society of India, 2015Indian Society of Nephrology
FAQs

PCV13 in Pulmonology
 

RoleComplicationsClinical DataRecommendations

PCV13 in Nephrology
 

RoleClinical DataRecommendations

PCV13 in Oncology
 

RoleClinical DataRecommendations

PCV13 in Rheumatology
 

RoleComplicationsDataRecommendationsConsensus

PCV13 in Diabetes
 

RoleComplicationsDataRecommendations

PCV13 in HIV Infection
 

RoleBurdenPulmonary InfectionDataEfficacyRecommendations

PCV13 in Cardiology
 

RoleBurdenComplicationsDataRecommendations
Resources

Resources

Summary of Prescribing InformationDownloadable ResourcesEvents and WebinarsLatest Articles

The Geriatric Society of India, 2015

Indian Recommendations for Vaccination in Older Adults by the Geriatric Society of India, 20151

   

Indications

   

Both the vaccines are recommended for all individuals above the age of 50 years and for those with the following conditions:

  1. Persons aged 50 years and above. 
     
  2. Persons with certain underlying medical conditions, such as coronary artery disease, congestive heart failure, cardiomyopathy, diabetes mellitus, bronchial asthma, chronic obstructive pulmonary disease, cirrhosis of liver and CRF
     
  3. Immunocompromised persons who are at high risk for pneumococcal infections, such as immunoglobin deficiency, HIV infection, leukaemia, lymphoma, multiple myeloma, Hodgkin’s disease, non-Hodgkin’s lymphoma, disseminated malignancy, who exhibit either a decreased responsiveness to vaccination or a greater decline in serum antibody concentrations.
     
  4. Persons with organ or bone marrow transplantation.
     
  5. Persons receiving long-term therapy with corticosteroids or immunosuppressive agents.
     
  6. Persons who have undergone splenectomy, or exhibit anatomic asplenia or sickle cell disease as they exhibit reduced clearance of encapsulated bacteria from the blood stream.
     
  7. Chronic smokers.
     
  8. Persons suffering from sleep disorders.
     
  9. Persons who are prone to nocturnal aspirations.

   

Schedule of Vaccination

   

PCV13 Is administered at a dose of 0.5 mL intramuscularly. The preferred site is the deltoid muscle of the upper arm.

  • PCV13 may have an edge in those elderly patients who have previously received PPSV23 to maintain the immune protection.
  • PCV13 may be the preferred vaccine in vaccine-native or previously vaccinated adults.
  • In case both the vaccines are considered, PCV13 should be administered first, followed by PPSV23.
  • For certain risk groups, like populations who are immunosuppressed or immunocompromised, if previously unvaccinated, a dose of PCV13 is recommended, followed by a dose of PPVS23 8 weeks later.

   

PPSV23 is given only once as a single dose to elderly persons.

   

Revaccination with PPSV23 may be recommended for persons exhibiting an increased risk of pneumococcal infection and to those who are likely to have a rapid decline in pneumococcal antibody levels provided that 5 years have elapsed since getting the first dose of pneumococcal vaccine.1

   

Mass Gatherings

   

The PREVENT expert opinion in Saudi Arabia based on the available data and circumstances has concluded that in mass gatherings, there is greater vulnerability of pilgrims due to age and previous illnesses, intense crowding and air pollution, and hence, the pilgrims should be advised to receive pneumococcal vaccine.2

   

The consensus recommendation for India and Bangladesh for the use of pneumococcal vaccine in mass gatherings and for Hajj pilgrims recommends that3:

  • PCV13 may be recommended 4 weeks before starting Hajj pilgrimage, depending on the economic status of the individuals
  • PPSV23 may be administered in these individuals upon return from the pilgrimage based on their risk status

Similar recommendations have been made by the Geriatric Society of India, 2015, and the IAOH.4,5
The IMA recommends mandatory PCV13 vaccination for Hajj pilgrims (adults aged >65 years).6

   

   

CRF, chronic renal failure; HIV, human immunodeficiency virus; IMA, Indian Medical Association; IAOH, Indian Association of Occupational Health; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.

   

References:

Sharma OP, ed. Indian Guidelines for Vaccination in Older Adults – A Guide for Geriatricians, Internists, Chest Physicians, Surgeons, Gynaecologists, Diabetologists, Cardiologists, Family Physicians. Geriatric Society of India; 2015.Rashid H, Muttalif ARA, Dahlan ZBM, et al. The potential for pneumococcal vaccination in Hajj pilgrims: expert opinion. Travel Med Infect Dis. 2013;11:288-294.Mathai D, Shamsuzzaman AK, Feroz AA, et al. Consensus recommendation for India and Bangladesh for the use of pneumococcal vaccine in mass gatherings with special reference to Hajj pilgrims. J Glob Infect Dis. 2016;8(4):129-138.Dhar R. Review of guidelines for the use of vaccines to prevent community-acquired pneumonia in Indian adults. JAPI. Supplement. 2016;64:45-51. Accessed May 17, 2022.
http://www.japi.org/December_2016_Special_Issue/pdf/13.pdf
Rajgopal T. Guidebook on Adult Immunization in Occupational Health Settings Healthy Worker: Key to Productivity and Sustainability. United Web Network; 2020. Accessed May 17, 2022. 
https://storage.unitedwebnetwork.com/files/162/b8a89025513aba3a9c888c097e204122.pdf
Tandon RN, Ravindra W, Monga VK. Life Course Immunization Guidebook. A Quick Reference Guide. Indian Medical Association; 2018. May 17, 2022.
https://www.ima-india.org/ima/pdfdata/IMA_LifeCourse_Immunization_Guide_2018_DEC21.pdf

   

Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

   

PP-PRV-IND-0268 July 2022


Recommendations for Use

FAQs

FAQs related to different fields

Learn more

Dosing

Help protect your adult patients against pneumococcal pneumonia with single-dose administration

Learn more

   

Efficacy

Efficacy proven by the CAPiTA study

Learn more

   

Recommendations for Use

The ACIP recommends routine use of PCV13 among adults

Learn more

   

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-PRV-IND-0268

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 14 July 2022
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
​PP-UNP-IND-0012 14 July 2022